San Francisco startup Structure Therapeutics is likewise focusing on an oral, when-daily GLP-1 drug known as GSBR-1290—the drug surpassed Wall Avenue’s expectations in June whenever a mid-phase study confirmed common weight loss of around six% and it options to begin One more mid-stage trial to the top of the calendar year—that founder and CE